Dentsply Sirona 10-Q: Q3 Loss, $75M Securities Settlement, Zero Free Cash Flow
XRAY is trading near its 52-week low of $8.32 (4.8% above the low).
Summary
Dentsply Sirona's Q3 10-Q shows $836 million in sales and a $0.01 loss per share, plus a $75 million insured settlement of the 2024 securities suit and zero free cash flow for the quarter.
Key Events · Earnings and Guidance · XRAY
-
Q3 Sales Fall 7.6%
Net sales were $836 million versus $904 million a year ago, with a GAAP diluted loss of $0.01 per share against a $2.14 loss last year.
-
$75M Securities Settlement
An October 20, 2026 MOU settles the 2024 securities litigation for $75 million, funded by D&O insurers with an offsetting receivable, so no P&L impact; court approval is still required.
-
Accounting Change Lifts Results
A revised intercompany inventory profit-elimination method added about $30 million, or $0.15 per share, to net income for the quarter and nine months; the company says equivalent impacts are not expected in future periods.
-
Cash and Free Cash Flow Thin
Cash fell to $195 million from $326 million at December 31, 2025; nine-month operating cash flow was $171 million and Q3 free cash flow was $0 million.
Analysis · XRAY · Industrial Applications And Services
The quarter was already public, but the 10-Q fills in what the 8-K did not. It discloses a $75 million settlement of the 2024 Byte-related securities class action, fully insured so there is no P&L hit, and a $30 million one-time boost from a change in inventory accounting that flattered the quarter. Meanwhile the balance sheet is thinning: cash fell to $195 million from $326 million at year-end while free cash flow was zero. With the stock near its 52-week low, a suspended dividend, leverage covenants loosened only through year-end 2026, and a trimmed outlook, the focus stays on cash generation rather than the headline loss.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, XRAY was trading at $8.72 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $2B. The 52-week trading range was $8.32 to $14.76. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.